Top Tweets for #lowgradeserous
#GY019
#LowGradeSerous #OvarianCancer
Paclitaxel + carboplatin + letrozole π letrozole
β letrozole arm did NOT demonstrate non-inferiority
β No stat. diff. in PFS or OS
π Signal that No residual disease + letrozole alone may benefit
βοΈ Chemo remains standard
5/6
#RAMP201 Long Term Safety & Efficacy
#LowGradeSerous #OvarianCancer
β
median DOR 31.1mo KRAS mut
β
median DOR 12.0mo KRAS wt
β
median PFS 19.6mo KRAS mut
β
median PFS 12.7mo KRAS wt
β
after 1yr, 30-52% pts still on tx
Effective & promising! Phase3 trial coming..
4/6
I am very thankful to @ocrfaustralia for funding my research to conduct essential preclinical validation of new combination therapeutics for patients suffering with low-grade serous ovarian cancer. #lowgradeserous #ovariancancer #RareDisease
Attending @SGO_Org's Annual Meeting on Women's Cancer? Stop by our Booth 420 to learn more about our pipeline and advancements in #lowgradeserous #ovariancancer or #LGSOC.
#SGOMtg #PowerofSharedPurpose
Today @US_FDA granted Orphan Drug Designation to avutometinib alone or in combination with defactinib for #lowgradeserous #ovariancancer, reinforcing our commitment to deliver new treatment options for the more than 6,000 US women affected by #LGSOC.
https://t.co/cBs0YKoIp8
2/3 of American women feel they have no control over their ovarian health.
This is shocking β women point to the need for more patient education when it comes to their #lowgradeserous #ovariancancer or #LGSOC.
To learn more visit: https://t.co/rSTqrDnb85
We are committed to supporting research offering breakthrough cancer therapy to patients so that no one, including those with rare diseases like #lowgradeserous #ovariancancer #LGSOC, runs out of treatment options. #DiseaseDay #RareDiseases
I am so proud of my amazing post-doc/senior research officer, Dr Kathleen Pishas, for being the top applicant for the VCA mid-career award. She is doing incredible work in the #lowgradeserous ovarian cancer space, and I cant wait to see what she achieves with this fellowship
As 2024 begins, we're celebrating the incredible progress made last year for the #lowgradeserous #ovariancancer #LGSOC community. We look forward to supporting this community through the continued progress to come throughout this year. Learn more: https://t.co/VC06iH7wfz
The path to diagnosis is not an easy one if you have #lowgradeserous #ovariancancer. Learn more about the experiences people living with #LGSOC shared in the #LGSOCPatientImpactSurvey: https://t.co/Gtbc51h2a3
In a step toward moving a new therapy forward for patients w/ #lowgradeserous #ovariancancer the #RAMP301 Phase 3 confirmatory trial designed to further assess the effectiveness & safety of avutometinib & defactinib for recurrent #LGSOC is open & enrolling https://t.co/rrAoLc84K5
From symptom onset, the average time to diagnosis #lowgradeserous #ovariancancer is 3 years the #LGSOCPatientImpactSurvey revealed. This delayed diagnosis directly impacts treatment outcomes. Learn more about the #LGSOC diagnosis journey: https://t.co/Gtbc51hzZB
The #LGSOCPatientImpactSurvey found that few women know the warning signs or about low-grade serous ovarian cancer itself. Read more from @TODAYshow to learn about one womanβs experience with #lowgradeserous #ovariancancer https://t.co/35naQOMAEh
$VSTM CMO Louis Denis shares power of findings from the #LGSOCPatientImpactSurvey to shape the treatment journey of patients with #lowgradeserous #ovariancancer #gyncsm. Learn more: https://t.co/Gtbc51hzZB
#Healthcareproviders: Introducing Letβs Talk About LGSOC for HCPs, a new resource to support doctors treating patients with a rare form of #ovariancancer, #lowgradeserous #LGSOC. Visit the website to learn more: https://t.co/MUMfTL27QT
βI firmly believe that by bridging innovative research with robust community engagement, we create an empowering environment where those impacted by #lowgradeserous #ovariancancer feel heard, understood & supported.β Hear more from $VSTM CEO Dan Paterson https://t.co/bMFtFoHemo
We are pleased to present results from the first-ever, multi-national #LGSOCPatientImpactSurvey, revealing the unique challenges experienced by people living with #lowgradeserous #ovariancancer #gyncsm. Learn more: https://t.co/Gtbc51h2a3
Dr. Grisham presented results of planned subgroup analysis of RAMP 201 trial, showing efficacy & safety of avutometinib & defactinib in recurrent #lowgradeserous #ovariancancer following prior systemic therapy at Annual Global Meeting of @IGCSociety. https://t.co/dn2AD97whf
No patient with cancer should run out of options. From our lead program in #lowgradeserous #ovariancancer to KRAS mt non-small cell lung cancer & other RAS-Pathway driven cancers, our goal is to find solutions to cancers with high unmet need. Learn more: https://t.co/55Xtpfs0OU
Thank you to @NOCC_National for their tremendous work to raise awareness & resources for #ovariancancer at the #TogetherInTeal walk. We are proud to support the work of the community during #OCAM in September & all year long. Learn more: https://t.co/TvdKjSJonE #lowgradeserous
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.1M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
108.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.3M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
86.8M followers
Taylor Swift
@taylorswift13
80.6M followers
Lady Gaga
@ladygaga
72.1M followers
Kim Kardashian
@kimkardashian
69.4M followers
YouTube
@youtube
68.6M followers
Virat Kohli
@imvkohli
68.5M followers
Bill Gates
@billgates
63.4M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61M followers
X
@x
60.9M followers
CNN Breaking News
@cnnbrk
59.9M followers